Hide metadata

dc.contributor.authorTelle-Hansen, Vibeke H
dc.contributor.authorChristensen, Jacob J
dc.contributor.authorFormo, Gulla A
dc.contributor.authorHolven, Kirsten B
dc.contributor.authorUlven, Stine M
dc.date.accessioned2020-05-12T05:03:17Z
dc.date.available2020-05-12T05:03:17Z
dc.date.issued2020
dc.identifier.citationLipids in Health and Disease. 2020 May 09;19(1):90
dc.identifier.urihttp://hdl.handle.net/10852/75468
dc.description.abstractBackground The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as “metabolically healthy obese” (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite this, the MHO phenotype is still sub-optimally characterized with respect to a comprehensive risk assessment. Our aim was to increase the understanding of metabolic alterations associated with healthy and unhealthy obesity. Methods In this cross-sectional study, men and women (18–70 years) with obesity (body mass index (BMI) ≥ 30 kg/m2) or normal weight (NW) (BMI ≤ 25 kg/m2) were classified with MHO (n = 9), MUO (n = 10) or NW (n = 11) according to weight, lipid profile and glycemic regulation. We characterized individuals by comprehensive metabolic profiling using a commercial available high-throughput proton NMR metabolomics platform. Plasma fatty acid profile, including short chain fatty acids, was measured using gas chromatography. Results The concentrations of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) subclasses were overall significantly higher, and high density lipoprotein (HDL) subclasses lower in MUO compared with MHO. VLDL and IDL subclasses were significantly lower and HDL subclasses were higher in NW compared with MHO. The concentration of isoleucine, leucine and valine was significantly higher in MUO compared with MHO, and the concentration phenylalanine was lower in NW subjects compared with MHO. The fatty acid profile in MHO was overall more favorable compared with MUO. Conclusions Comprehensive metabolic profiling supports that MHO subjects have intermediate-stage cardiovascular disease risk marker profile compared with NW and MUO subjects. Clinical trial registration number NCT01034436, Fatty acid quality and overweight (FO-study). Graphical abstract
dc.language.isoeng
dc.rightsThe Author(s); licensee BioMed Central Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleA comprehensive metabolic profiling of the metabolically healthy obesity phenotype
dc.typeJournal article
dc.date.updated2020-05-12T05:03:18Z
dc.creator.authorTelle-Hansen, Vibeke H
dc.creator.authorChristensen, Jacob J
dc.creator.authorFormo, Gulla A
dc.creator.authorHolven, Kirsten B
dc.creator.authorUlven, Stine M
dc.identifier.cristin1810892
dc.identifier.doihttps://doi.org/10.1186/s12944-020-01273-z
dc.identifier.urnURN:NBN:no-78510
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/75468/1/12944_2020_Article_1273.pdf
dc.type.versionPublishedVersion
cristin.articleid90


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International